TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25033925
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU Vitamin D3 at monthly intervals
Study: 21577132
Drug: Iomeprol 400
Normalized name: Iomeprol 400 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 400 at 3 mL/s (IDR = 1.2 gI/s)
Study: 21577132
Drug: Iomeprol 400
Normalized name: Iomeprol 400 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 400 at 4 mL/s (IDR = 1.6 gI/s)
Study: 21577132
Drug: Iomeprol 300
Normalized name: Iomeprol 300 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 300 at 5.4 mL/s (IDR = 1.6 gI/s)
Study: 21577132
Drug: Iomeprol 300
Normalized name: Iomeprol 300 MG/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol 300 at 4 mL/s (IDR = 1.2 gI/s)
Study: 20399996
Drug: Dispersible tablet
Normalized name: Aspirin 75 mg orodispersible tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablet formulation of ampicillin/probenecid (1500 mg total; 250 mg each containing ampicillin 194.5 mg and probenecid 55.5 mg)
Study: 20399996
Drug: Branded capsule
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded capsule formulation of ampicillin/probenecid (1500 mg total; 250 mg each containing ampicillin 194.5 mg and probenecid 55.5 mg)
Study: 18061070
Drug: GTN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN treatment for 48 hours
Study: 9806691
Drug: Intraarticular triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular triamcinolone acetonide 10 mg in isotonic saline 20 mL
Study: 9806691
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline 20 mL
Study: 337493
Drug: Methylphenidate (larger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (larger doses)
Study: 30782672
Drug: Group Metacognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Metacognitive Grief Therapy (MCGT)
Study: 27394187
Drug: Regular therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular therapy alone (C group)
Study: 21729732
Drug: PCV-7 vaccine
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCV-7 vaccine
Study: 22916192
Drug: Serogroup C
Normalized name: Neisseria meningitidis serogroup C Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serogroup C meningococcal conjugate vaccine
Study: 2122630
Drug: L-carnitine 10
Normalized name: coenzyme Q10/L-carnitine 100 mg-20 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine 10 mg/kg (n = 6)
Study: 366182
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous indomethacin
Study: 366182
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous riboflavin (placebo)
Study: 23312888
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus paclitaxel (10 mg/kg on days 1 and 15; 90 mg/m² on days 1, 8, and 15, every 4 weeks)
Study: 23312888
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus capecitabine (15 mg/kg on day 1; 1000 mg/m² twice daily on days 1-14, every 3 weeks)
Study: 15722700
Drug: Intensive telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive telephone follow-up (12 weekly phone calls)
Study: 12823593
Drug: 1.0 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 microg/kg peginterferon‐alpha‐2b twice weekly for 4 weeks
Study: 12823593
Drug: 1.0 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 microg/kg peginterferon‐alpha‐2b once weekly for 4 weeks
Study: 10910848
Drug: droperidol (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol (0.625 mg)
Study: 8237746
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (12,500 units subcutaneously every 12 hours for three doses after sheath removal)
Study: 8237746
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin (1000 units/hour for 12 to 18 hours)
Study: 27149489
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus before sedation, continuous infusion at 2 mg/kg/h during sedation)
Study: 27149489
Drug: Control (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normal saline, same bolus and infusion volumes as lidocaine)
Study: 25304475
Drug: Continuous right
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous right thoracic paravertebral block with 10-mL bolus of 0.2% ropivacaine followed by continuous infusion of 6 mL/h for 24 hours (PVB group)
Study: 25304475
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered through the same catheter scheme (control group)
Study: 22860302
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg x kg(‐1) on induction)
Study: 19545320
Drug: Instructions associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructions associated with the home use of a disclosing agent (1% neutral red)
Study: 19545320
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and denture hygiene instructions
Study: 18467544
Drug: Nutrient supplement
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient supplement (protein, carbohydrate, calcium, and vitamin D)
Study: 12633127
Drug: Integrated family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated family and individual therapy (IFIT)
Study: 8550792
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) 2 IU/m2
Study: 8550792
Drug: Insulin-like Growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like Growth Factor I (IGF‐I) 80 micrograms/kg
Study: 1801154
Drug: Amocarzine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amocarzine 3 mg/kg oral dose twice daily for three days (fed patients)
Study: 1801154
Drug: Amocarzine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amocarzine 3 mg/kg oral dose twice daily for three days (fasting patients)
Study: 29874535
Drug: Mifepristone pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone pretreatment (200 mg orally) followed by misoprostol (800 μg vaginally)
Study: 29874535
Drug: Misoprostol alone
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol alone (800 μg vaginally)
Study: 17385022
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (HC)
Study: 17385022
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (DEX)
Study: 17385022
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (MPL)
Study: 17385022
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (PNL)
Study: 1284163
Drug: gallopamil SR
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil SR 100 mg twice a day
Study: 6142717
Drug: Liquid oral
Normalized name: M-End Liquid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral solution of bromazepam (3 mg)
Study: 6142717
Drug: Liquid oral
Normalized name: M-End Liquid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid oral solution of bromazepam (1.5 mg)
Study: 31540613
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for cocaine use disorders (CUD)
Study: 27184297
Drug: Attention Bias
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Bias Modification Therapy (ABMT)
Study: 23103033
Drug: Control stents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control stents (bare metal or drug-eluting)
Study: 20840318
Drug: Zibotentan 15
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan 15 mg
Study: 20840318
Drug: Zibotentan 10
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan 10 mg
Study: 17880872
Drug: Intralesional autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional autologous blood injection
Study: 16115973
Drug: Fentanyl injection
Normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl injection over 2 seconds
Study: 16115973
Drug: Fentanyl injection
Normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl injection over 15 seconds
Study: 16115973
Drug: Fentanyl injection
Normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl injection over 30 seconds
Study: 7957497
Drug: rhEPO (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO (500 U kg‐1 body weight twice weekly during a 3 week period)
Study: 3669729
Drug: MgSO4 inhalation
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MgSO4 inhalation
Study: 31960624
Drug: Tezepelumab 35
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab 35 mg
Study: 31960624
Drug: Tezepelumab 105
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab 105 mg
Study: 31960624
Drug: Tezepelumab 280
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab 280 mg
Study: 20864916
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFOX6 (oxaliplatin 85 mg/m², leucovorin 350 mg, and 5-fluorouracil 400 mg/m² bolus; 2.4 g/m² infusion, 46 h) day 1; bevacizumab 5 mg/kg on day 1; cetuximab 400 mg/m² on day 1, then 250 mg/m² on days 1 and 8, every 14 days until progressive disease (PD)
Study: 8977914
Drug: Calcium carbasalate
Normalized name: carbasalate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium carbasalate (equivalent to aspirin 325 mg daily, single dose 6 hours post-operation, repeated for 7 days)
Study: 1587379
Drug: 25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms 17 beta-estradiol (Vagifem) administered as a vaginal tablet, treated once daily for 2 weeks and twice a week for 10 weeks
Study: 31645444
Drug: Adenovirus Type
Normalized name: Adenovirus types 4 and 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenovirus Type 5-Based HIV-1 Vaccines
Study: 24059649
Drug: Inulin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (10 g/d for 8 weeks)
Study: 22291886
Drug: Clonidine 150
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 150 µg orally
Study: 22291886
Drug: Clonidine 75
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 75 µg orally
Study: 22291886
Drug: Clonidine 0
Normalized name: clonidine 0.17 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0 µg (placebo)
Study: 16362593
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin 1x 20 microg for 2 months
Study: 16362593
Drug: Conditioning therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning therapy for 2 months
Study: 16362593
Drug: Intranasal isotonic
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal isotonic solutions (placebo)
Study: 10073511
Drug: mifepristone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: mifepristone (all doses)
Study: 2149565
Drug: Trazodone hydrochloride
Normalized name: Trazodone Hydrochloride
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trazodone hydrochloride (average dose 201 mg)
Study: 2149565
Drug: Placebo (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (average dose 238 mg)
Study: 30282056
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A)
Study: 24990200
Drug: 5-mg once-daily
Normalized name: lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mg once-daily tadalafil
Study: 24990200
Drug: 5-mg alternate-day
Normalized name: Alternaria alternata allergenic extract 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg alternate-day tadalafil
Study: 16830130
Drug: MDMA 0
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 0 mg with alcohol
Study: 10997956
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (1.0 g CHO.kg body mass(‐1) prior to and 0.5 g CHO.kg body mass(‐1) every 10 minutes during IRT)
Study: 26261114
Drug: Active learning
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active learning modules (case scenarios, critical appraisal of prescriptions, drug identification)
Study: 23651425
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone undecanoate (1000 mg)
Study: 18979716
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers
Study: 18979716
Drug: New therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapies under preclinical investigation or early stage clinical trials
Study: 10764418
Drug: Norepinephrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (10 micromol/L) exposure in isolated cardiomyocytes
Study: 8650928
Drug: Wobenzym (enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wobenzym (enzyme therapy)
Study: 8650928
Drug: Lynestrenol (hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lynestrenol (hormone therapy)
Study: 1611639
Drug: Diltiazem 180
Normalized name: diltiazem 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 180 mg, 360 mg, and 540 mg once daily for two weeks
Study: 6146045
Drug: Children not
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children not receiving vitamin A supplements (case-control analysis)
Study: 29356207
Drug: Adjunctive mexiletine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive mexiletine therapy
Study: 27021829
Drug: Parent involvement
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent involvement intervention (weekly newsletters and text messages for 5 weeks)
Study: 24060708
Drug: Intensive interdisciplinary
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive interdisciplinary pain treatment (IIPT)
Study: 22488252
Drug: Fluoride-supplemented milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride-supplemented milk (200 ml with 5 mg F/l as NaF once a day)
Study: 22488252
Drug: Unsupplemented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupplemented milk (200 ml)
Study: 18633021
Drug: Palonosetron 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.025 mg
Study: 18633021
Drug: Palonosetron 0.050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.050 mg
Study: 2066455
Drug: High-dose fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluoxetine (median 80 mg/day)
Study: 2066455
Drug: Standard-dose imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose imipramine (median 200 mg/day)
Study: 6190888
Drug: Intravenous metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous metronidazole alone
Study: 6190888
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metronidazole and gentamicin
Study: 6190888
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of bowel preparation (poor)
Study: 29505321
Drug: Home Exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home Exercise Program (HEP) consisting of three static balance exercises: feet-together, single-leg stance, and tandem, performed twice for 30-60 seconds, once per day, 3 days per week for 12 weeks.
Study: 24832388
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg fentanyl (group F)
Study: 24832388
Drug: 0.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg/kg dexmedetomidine (group D0.5)
Study: 24832388
Drug: 1.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg/kg dexmedetomidine (group D1.0)
Study: 20437859
Drug: Short-course radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiation plus adjuvant temozolomide (150-200 mg/m² for 5 days every 28-day cycle)
Study: 9513589
Drug: 23 valent
Normalized name: pneumococcal polysaccharide vaccine, 23 valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 valent pneumococcal vaccine
Study: 7608314
Drug: GITS (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: GITS (240 mg)
Study: 7608314
Drug: GITS (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GITS (120 mg)
Study: 7608314
Drug: PeHCl solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PeHCl solution (given every 6 hours)
Study: 7608314
Drug: Timed-release 12-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed-release 12-hour pseudoephedrine capsule (given every 12 hours)
Study: 2364843
Drug: Standard nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nicardipine (20 mg)
Study: 2364843
Drug: Sustained-release nicardipine
Normalized name: nicardipine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nicardipine (30 mg twice a day)
Study: 2364843
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of nicardipine
Study: 30920602
Drug: Aerobic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic and resistance exercise intervention (supervised sessions thrice weekly for 16 weeks)
Study: 26881502
Drug: Supraclavicular radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supraclavicular radiation therapy (SC‐RT)
Study: 21044897
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in low RVP (≤ 50%)
Study: 21044897
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in high RVP (> 50%)
Study: 21044897
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in low RVP (≤ 50%) during late phase
Study: 21044897
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy in high RVP (> 50%) during late phase
Study: 11697839
Drug: irinotecan 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 175 mg/m2 given on days 1 and 10, repeated every three weeks for a total of six courses
Study: 3408037
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nicergoline
Study: 21722959
Drug: Intramuscular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketamine (K2: 10 mg and 25 mg doses at 11 and 4 hours preoperatively)
Study: 21722959
Drug: Intramuscular ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ketamine (K3: 5 mg, 10 mg, and 25 mg doses at 17, 11, and 4 hours preoperatively)
Study: 21722959
Drug: 1-ketamine-injection (K1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-ketamine-injection (K1: 25 mg at 4 hours preoperatively)
Study: 22233522
Drug: Calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitors (CNI) continuation
Study: 11407442
Drug: Targeted maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted maintenance pharmacotherapy
Study: 11407442
Drug: Standard-dose maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose maintenance neuroleptic treatment
Study: 11407442
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Targeted and Standard-dose)
Study: 8986684
Drug: E1S (estrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: E1S (estrone sulfate) 0.625 mg
Study: 8986684
Drug: EqS (equilin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EqS (equilin sulfate) 0.3 mg
Study: 8986684
Drug: 17 alpha-ES
Normalized name: 17-alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-ES (17 alpha-dihydroequilin sulfate) 0.2 mg
Study: 8275614
Drug: Naringin capsule
Normalized name: Naringin
DrugBank: Naringin (DB16859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naringin capsule
Study: 2886340
Drug: Beta-blockers +
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers + Chlorthalidone (BB + CTD)
Study: 25363178
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg PRN and hydration (control group)
Study: 18565217
Drug: Systemic methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic methotrexate (MTX) - single dose intramuscular regimen (1 mg/kg)